Targeting IL-6 in cholangiocarcinoma therapy

Justin L. Mott, Gregory J. Gores

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

In this issue of the Journal, Cheon and coworkers have examined the utility of serum IL-6 values as a biomarker for cholangiocarcinoma (CCA). Serum IL-6 values were increased in patients with CCA as compared to controls or patients with hepatocellular carcinoma. IL-6 levels also correlated with tumor thickness (a surrogate for tumor burden) as examined by intraductal ultrasonography, a novel approach for assessing CCA tumor burden. Following photodynamic therapy, serum IL-6 values decreased. This study suggests IL-6 may be a biomarker for CCA, confirms the efficacy of photodynamic therapy (PDT) as an antineoplastic therapy, and implies that targeted IL-6 therapy may be beneficial in CCA.

Original languageEnglish (US)
Pages (from-to)2171-2172
Number of pages2
JournalAmerican Journal of Gastroenterology
Volume102
Issue number10
DOIs
StatePublished - Oct 1 2007

Fingerprint

Cholangiocarcinoma
Interleukin-6
Photochemotherapy
Tumor Burden
Therapeutics
Biomarkers
Serum
Antineoplastic Agents
Hepatocellular Carcinoma
Ultrasonography
Neoplasms

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Targeting IL-6 in cholangiocarcinoma therapy. / Mott, Justin L.; Gores, Gregory J.

In: American Journal of Gastroenterology, Vol. 102, No. 10, 01.10.2007, p. 2171-2172.

Research output: Contribution to journalReview article

Mott, Justin L. ; Gores, Gregory J. / Targeting IL-6 in cholangiocarcinoma therapy. In: American Journal of Gastroenterology. 2007 ; Vol. 102, No. 10. pp. 2171-2172.
@article{6ac4f8227fe04fd0bf06accb13b609ad,
title = "Targeting IL-6 in cholangiocarcinoma therapy",
abstract = "In this issue of the Journal, Cheon and coworkers have examined the utility of serum IL-6 values as a biomarker for cholangiocarcinoma (CCA). Serum IL-6 values were increased in patients with CCA as compared to controls or patients with hepatocellular carcinoma. IL-6 levels also correlated with tumor thickness (a surrogate for tumor burden) as examined by intraductal ultrasonography, a novel approach for assessing CCA tumor burden. Following photodynamic therapy, serum IL-6 values decreased. This study suggests IL-6 may be a biomarker for CCA, confirms the efficacy of photodynamic therapy (PDT) as an antineoplastic therapy, and implies that targeted IL-6 therapy may be beneficial in CCA.",
author = "Mott, {Justin L.} and Gores, {Gregory J.}",
year = "2007",
month = "10",
day = "1",
doi = "10.1111/j.1572-0241.2007.01394.x",
language = "English (US)",
volume = "102",
pages = "2171--2172",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Targeting IL-6 in cholangiocarcinoma therapy

AU - Mott, Justin L.

AU - Gores, Gregory J.

PY - 2007/10/1

Y1 - 2007/10/1

N2 - In this issue of the Journal, Cheon and coworkers have examined the utility of serum IL-6 values as a biomarker for cholangiocarcinoma (CCA). Serum IL-6 values were increased in patients with CCA as compared to controls or patients with hepatocellular carcinoma. IL-6 levels also correlated with tumor thickness (a surrogate for tumor burden) as examined by intraductal ultrasonography, a novel approach for assessing CCA tumor burden. Following photodynamic therapy, serum IL-6 values decreased. This study suggests IL-6 may be a biomarker for CCA, confirms the efficacy of photodynamic therapy (PDT) as an antineoplastic therapy, and implies that targeted IL-6 therapy may be beneficial in CCA.

AB - In this issue of the Journal, Cheon and coworkers have examined the utility of serum IL-6 values as a biomarker for cholangiocarcinoma (CCA). Serum IL-6 values were increased in patients with CCA as compared to controls or patients with hepatocellular carcinoma. IL-6 levels also correlated with tumor thickness (a surrogate for tumor burden) as examined by intraductal ultrasonography, a novel approach for assessing CCA tumor burden. Following photodynamic therapy, serum IL-6 values decreased. This study suggests IL-6 may be a biomarker for CCA, confirms the efficacy of photodynamic therapy (PDT) as an antineoplastic therapy, and implies that targeted IL-6 therapy may be beneficial in CCA.

UR - http://www.scopus.com/inward/record.url?scp=34848816778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848816778&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2007.01394.x

DO - 10.1111/j.1572-0241.2007.01394.x

M3 - Review article

C2 - 17897336

AN - SCOPUS:34848816778

VL - 102

SP - 2171

EP - 2172

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 10

ER -